These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 21690412)

  • 1. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.
    Schaefer W; Regula JT; Bähner M; Schanzer J; Croasdale R; Dürr H; Gassner C; Georges G; Kettenberger H; Imhof-Jung S; Schwaiger M; Stubenrauch KG; Sustmann C; Thomas M; Scheuer W; Klein C
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11187-92. PubMed ID: 21690412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of CrossMAb technology for the generation of bi- and multispecific antibodies.
    Klein C; Schaefer W; Regula JT
    MAbs; 2016; 8(6):1010-20. PubMed ID: 27285945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G
    De Nardis C; Hendriks LJA; Poirier E; Arvinte T; Gros P; Bakker ABH; de Kruif J
    J Biol Chem; 2017 Sep; 292(35):14706-14717. PubMed ID: 28655766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies.
    Bönisch M; Sellmann C; Maresch D; Halbig C; Becker S; Toleikis L; Hock B; Rüker F
    Protein Eng Des Sel; 2017 Sep; 30(9):685-696. PubMed ID: 28981885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.
    Wu X; Sereno AJ; Huang F; Zhang K; Batt M; Fitchett JR; He D; Rick HL; Conner EM; Demarest SJ
    MAbs; 2015; 7(2):364-76. PubMed ID: 25611120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.
    Lewis SM; Wu X; Pustilnik A; Sereno A; Huang F; Rick HL; Guntas G; Leaver-Fay A; Smith EM; Ho C; Hansen-Estruch C; Chamberlain AK; Truhlar SM; Conner EM; Atwell S; Kuhlman B; Demarest SJ
    Nat Biotechnol; 2014 Feb; 32(2):191-8. PubMed ID: 24463572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving target cell specificity using a novel monovalent bispecific IgG design.
    Mazor Y; Oganesyan V; Yang C; Hansen A; Wang J; Liu H; Sachsenmeier K; Carlson M; Gadre DV; Borrok MJ; Yu XQ; Dall'Acqua W; Wu H; Chowdhury PS
    MAbs; 2015; 7(2):377-89. PubMed ID: 25621507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
    Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M
    Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain.
    Fenn S; Schiller CB; Griese JJ; Duerr H; Imhof-Jung S; Gassner C; Moelleken J; Regula JT; Schaefer W; Thomas M; Klein C; Hopfner KP; Kettenberger H
    PLoS One; 2013; 8(4):e61953. PubMed ID: 23613981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.
    Schaefer W; Völger HR; Lorenz S; Imhof-Jung S; Regula JT; Klein C; Mølhøj M
    MAbs; 2016; 8(1):49-55. PubMed ID: 26496506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.
    Klein C; Sustmann C; Thomas M; Stubenrauch K; Croasdale R; Schanzer J; Brinkmann U; Kettenberger H; Regula JT; Schaefer W
    MAbs; 2012; 4(6):653-63. PubMed ID: 22925968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering therapeutic bispecific antibodies using CrossMab technology.
    Klein C; Schaefer W; Regula JT; Dumontet C; Brinkmann U; Bacac M; Umaña P
    Methods; 2019 Feb; 154():21-31. PubMed ID: 30453028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The eIg technology to generate Ig-like bispecific antibodies.
    Kühl L; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new approach to produce IgG
    Zhao C; Zhang W; Gong G; Xie L; Wang MW; Hu Y
    Sci Rep; 2021 Sep; 11(1):18630. PubMed ID: 34545109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.
    Cooke HA; Arndt J; Quan C; Shapiro RI; Wen D; Foley S; Vecchi MM; Preyer M
    MAbs; 2018; 10(8):1248-1259. PubMed ID: 30215570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.
    Dillon M; Yin Y; Zhou J; McCarty L; Ellerman D; Slaga D; Junttila TT; Han G; Sandoval W; Ovacik MA; Lin K; Hu Z; Shen A; Corn JE; Spiess C; Carter PJ
    MAbs; 2017; 9(2):213-230. PubMed ID: 27929752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.